Skolarus, Ted A.
Hawley, Sarah T.
Forman, Jane
Sales, Anne E.
Sparks, Jordan B.
Metreger, Tabitha
Burns, Jennifer
Caram, Megan V.
Radhakrishnan, Archana
Dossett, Lesly A.
Makarov, Danil V.
Leppert, John T.
Shelton, Jeremy B.
Stensland, Kristian D.
Dunsmore, Jennifer
Maclennan, Steven
Saini, Sameer
Hollenbeck, Brent K.
Shahinian, Vahakn
Wittmann, Daniela A.
Deolankar, Varad
Sriram, S.
Funding for this research was provided by:
National Cancer Institute (R37 CA222885)
Article History
Received: 4 February 2024
Accepted: 4 March 2024
First Online: 9 April 2024
Declarations
:
: This study has been approved by the VA Ann Arbor Healthcare System IRB (IRB-2017-1047) and the University of Michigan IRB (HUM00133932). As this study is considered minimal risk, a waiver of documentation of signed informed consent and HIPAA Authorization was approved. Further information and documentation on IRB approval are available upon request.
: All authors consent for the manuscript to be published.
: The authors declare that they have no competing interests. Kristian Stensland is a member of the Editorial Board, Ted Skolarus is the Associate Editor, and Anne Sales is the co-Editor-in-Chief of <i>Implementation Science Communications</i>.